You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBIMyocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
AHTP-comet: development of an automated, high throughput comet assay system
SBC: Engineering Resources Group, Inc Topic: NIEHSPROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated Rodent Research Home Cage Monitoring System for Animal Welfare
SBC: Tricorder Array Technologies LLC Topic: 100PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology
SBC: Pneumax, LLC Topic: 113PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
The Point Digit: A ratcheting prosthetic finger using advanced rapid manufacturing technology
SBC: POINT DESIGNS, LLC Topic: NICHDThe Point DigitA Ratcheting Prosthetic Finger UsingAdvanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop and commercialize a purely mechanicalratcheting prosthetic fingerthe Point Digitwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s metacar ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Portable Device for Accurate Mouse Tail Vein Injection
SBC: Technology Commercialization Partners LLC Topic: ODPROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community Participation
SBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHDEvolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.
SBC: BIOMIMETIX JV LLC Topic: 102Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health